Clinical Trials Logo

Clinical Trial Summary

Under the premise of basic treatment, to explore the improvement effect of huperzine A injection on short-term and long-term neurocognitive dysfunction in patients with aneurysmal subarachnoid hemorrhage after interventional/surgical treatment.


Clinical Trial Description

Description: This is a randomized, controlled, single center, exploratory clinical trial. The subjects are divided into surgical treatment group and interventional treatment group. Each group is divided into test group and control group. The test group is given huperzine A injection (0.2mg/dose) every day, intramuscular injection, for a total of 8 days, and basic treatment is given at the same time; The control group was given basic treatment, and did not receive other neurotrophic drugs except basic drugs. This clinical trial is to evaluate the effect of huperzine A injection on the improvement of postoperative cognitive dysfunction in patients with aneurysmal subarachnoid hemorrhage. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05560373
Study type Interventional
Source Wanbangde Pharmaceutical Group Co., LTD
Contact Chen Jingsen
Phone 13666669121
Email furycjs@126.com
Status Not yet recruiting
Phase Phase 4
Start date September 30, 2022
Completion date September 30, 2024